Manhattan Scientifics Announces Rising Price & Volume

NEW YORK–(BUSINESS WIRE)–Manhattan Scientifics, Inc. (OTCQB:MHTX) owns 50+ Million shares of its former wholly-owned subsidiary cancer diagnostic company Imagion Biosystems Ltd. (AX:IBX). Volume trading yesterday exceeded 80 million shares @ high of AU $0.010. Manhattan Scientifics acquired and funded 10 years early R&D of IBX now anticipating possible US FDA approval to initiated human cancer testing.

About Imagion Biosystems

Imagion Biosystems (www.imgionbiosystems.com) is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

About Manhattan Scientifics, Inc.

Manhattan Scientifics, Inc. (www.mhtx.com) is focused on technology transfer and commercialization of transformative technologies. (Read more…)

Forward-looking statement

This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company’s actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.

Contacts

Manhattan Scientifics, Inc.

Manny Tsoupanarias, 917-688-4158

[email protected]
Or

Marvin Maslow, 917-923-3300

[email protected]